Cancer Prevention

Part of the Statistics for Biology and Health book series (SBH)


Cancer Risk Cancer Prevention Fecal Occult Blood Testing Microsimulation Model Cancer Prevention Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abrams D.B., 1999. Nicotine addiction: paradigms for research in the 21st century. Nicotine Tob Res 1:S211–S215.CrossRefGoogle Scholar
  2. Akushevich I., Kulminski A., Manton K., 2005. Life tables with covariates: life tables with covariates: dynamic model for nonlinear analysis of longitudinal data. Math Popul Stud 12(2):51–80.MATHMathSciNetCrossRefGoogle Scholar
  3. Akushevich I., Manton K.G., Kulminski A., Kovtun M., Kravchenko J., Yashin A. (2006) Population models for the health effects of ionizing radiation. Radiats Biol Radioecol 46(6):663–674.Google Scholar
  4. Akushevich I., Kravchenko, J.S., Manton K.G., 2007. Health based population forecasting: effects of smoking on mortality and fertility. Risk Anal 27(2):467–482.CrossRefGoogle Scholar
  5. Ames B.N., 1998. Micronutrients prevent cancer and delay ageing. Toxicol Lett 102–103:5–18.CrossRefGoogle Scholar
  6. Ames B.N., 1999a. Cancer prevention and diet: help from single nucleotide polymorphisms. PNAS 96(22):12216–12218.Google Scholar
  7. Ames B.N., 1999b. Micronutrient deficiencies. A major cause of DNA damage. Ann N Y Acad Sci.889:87–106.Google Scholar
  8. Anderson C.M., Burns D.M., Major J.M. et al., 2001. Changes in adolescent smoking behaviors in sequential birth cohorts. In: Burns D., Amacher R., Ruppert W. (Eds.). Changing Adolescent Smoking Prevalence. Smoking and Tobacco Control Monograph No. 14. NIH Publ. No. 02-5086. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, pp. 141–155.Google Scholar
  9. Artandi S.E., DePinho R.A., 2000. Mice without telomerase: what can they teach us about human cancer? Nat Med 6:852–855.CrossRefGoogle Scholar
  10. Ash A.S., Byrne-Logan S., 1998. How well do models work? Predicting health care costs. In Proceedings of the Section on Statistics in Epidemiology, American Statistical Association, August 1998, pp. 42–49.Google Scholar
  11. Badawi A.F., 2000. The role of prostaglandin synthesis in prostate cancer. BJU Int 85(4):451–462.CrossRefGoogle Scholar
  12. Ballard-Barbash R., Friedenreich C., Slattery M., Thune I., 2006. Obesity and body composition. In: Cancer Epidemiology and Prevention. Schottenfeld D., Fraumeni J.F. Jr. (Eds.). 3rd edition. Oxford: Oxford, University Press.Google Scholar
  13. Baron J.A., Sandler R.S., 2000. Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med 51:511–523.CrossRefGoogle Scholar
  14. Baron J.A., Cole B.F., Sandler R.S. et al., 2003. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899.CrossRefGoogle Scholar
  15. Bauer U., Johnson T., 2001. Predictors of tobacco use among adolescents in Florida, 1998–1999. In: Burns D., Amacher R., Ruppert W. (Eds.) Changing Adolescent Smoking Prevalence. Smoking and Tobacco Control Monograph No. 14. NIH Publ. No. 02-5086. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, pp. 121–140.Google Scholar
  16. Benamouzig R., Deyra J., Martin A. et al., 2003. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 125:328–336.CrossRefGoogle Scholar
  17. Bhattacharya J., Cutler D.M., Goldman D.P., Hurd M.D., Joyce G.F., Lakdawalla D.N., Panis C.W.A., Shang B., 2004. Disability forecasts and future Medicare costs. Front Health Policy Res, 7, September 2004.Google Scholar
  18. Bonithon-Kopp, C., Kronberg, O., Giacosa, A et al, 2000. Calcium and fiber supplementation in presentation of colorectal adenoma recurrence: a randomized intervention trial. Lancet 14:1300–1306.CrossRefGoogle Scholar
  19. Breslow L., Agran L., Breslow D.M. et al., 1977. Cancer control: implications from its history. J Natl Cancer Inst 59:671–686.Google Scholar
  20. Brunsvig P.E., Aamdal S., Gjertsen M.K. et al., 2006. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 55:1553–1564.CrossRefGoogle Scholar
  21. Bryan T.M., Englezou A., Gupta J. et al., 1995. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 14:4240–4248.Google Scholar
  22. Byers T.E., Mouchawar J., Marks J., Cady B., Lins N., Swanson G.M., Bal D.G., Eyre H., 1999. The American Cancer Society challenge goals. How far can cancer rates decline in the U.S. by the year 2015? Cancer 86(4):715–727.Google Scholar
  23. Cairncross F., (2007) Economics: age, health and wealth. Nature 448:875–876 (23 August 2007) | doi:10.1038/448875a; Published online 22 August 2007Google Scholar
  24. Carpenter E.L., Vonderheide R.H., 2006. Telomerase-based immunotherapy of cancer. Expert Opin Biol Ther 6:1031–1039.CrossRefGoogle Scholar
  25. Centers for Disease Control and Prevention, 1999. Best Practices for Comprehensive Tobacco Control Programs. Atlanta: CDC< National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.Google Scholar
  26. Centers for Disease Control and Prevention, 2000a. Cigarette smoking among adults – United States, 2002. MMWR 51:642–645.Google Scholar
  27. Centers for Disease Control and Prevention, 2000b. Use of FDA-approved pharmacologic treatments for tobacco dependence – United States, 1984–1998. MMWR 49:665–668.Google Scholar
  28. Centers for Disease Control and Prevention, 2002. Youth risk behavior surveillance - United States, 2001. MMWR Surveill Summ 51:SS4.Google Scholar
  29. Centers for Disease Control and Prevention, 2003. Cigarette smoking among adults – United States, 2001. MMWR 52:953–966.Google Scholar
  30. Chen K., Qiu J-L., Zhang Y., Zhao Y-W., 2003. Meta analysis of risk factors for colorectal cancer. World J Gastroenterol (7):1598–1600.Google Scholar
  31. Choi S., Singh S.V., 2005. Bax and Bak are required for apoptosis induction by sulforaphane, a cruciferous vegetable-derived cancer preventive agent. Cancer Res 65(5):2035–2043.CrossRefGoogle Scholar
  32. Colditz G.A., Gortmaker S.L., 1995. Cancer prevention strategies for the future: risk identification and preventive intervention. Milbank Q 73(4):621–651.CrossRefGoogle Scholar
  33. Correa P., Fontham E.T., Bravo J.C. et al., 2000. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 92:1881–1888.CrossRefGoogle Scholar
  34. Courneya K.S., 2003. Exercise in cancer survivors: biopsychosocial outcomes. Med Sci Sports Exerc 35:1846–1852.CrossRefGoogle Scholar
  35. Cover C.M. et al., 1998. Indole-3-carbinol inhibits the expression of cyclin-dependent kinase-6 and induces a G1 cell cycle arrest of human breast cancer cells independent of estrogen receptor signaling. J Biol Chem 273:3838–3847.CrossRefGoogle Scholar
  36. Cummings S.R., Eckert S., Krueger K.A. et al., 1999. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197.CrossRefGoogle Scholar
  37. Curry S.J., Byers T., Hewitt M. (Eds), 2003. Fulfilling the Potential of Cancer Prevention and Early Detection. Institute of Medicine, National Research Council of the National Academies. Washington, D.C.: The National Academies Press, 542 pages.Google Scholar
  38. Cuzick J., Forbes J., Edwards R. et al., 2002. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 360:817–824.CrossRefGoogle Scholar
  39. Devesa S.S., Young J.L. Jr., Brinton L.A. et al., 1989. Recent trends in cervix uteri cancer. Cancer 64:2184–2190.CrossRefGoogle Scholar
  40. Doll R. 1998. Uncovering the effects of smoking: historical perspective. Statist Meth Med Res 7:87–117.Google Scholar
  41. Doll R., 1992. The lessons of life: keynote address to the Nutrition and Cancer Conference. Cancer Research, Suppl. 52:2024S–2029S.Google Scholar
  42. Doll R., Peto,R., 1981. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 66(6):1191–1308.Google Scholar
  43. El-Bayoumy K. et al., 2006. Cancer chemoprevention by garlic and garlic-containing sulfur and selenium compounds. J Nutr 136(3):864S–869S.Google Scholar
  44. Emenaker N.J., Milner J.A., 2006. Eating for cancer prevention: a molecular approach. AgroFOOD Industry Hi-Tech 17(3):24–26.Google Scholar
  45. Everett S., Warren C., 2001. Trends and subgroup differences in tobacco use among high school students in the United States, 1991–1997. Changing Adolescent Smoking Prevalence. Smoking and Tobacco Control Monograph No. 14. NIH Publ. No. 02-5086. Bethesda, MD:U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, pp. 35–50.Google Scholar
  46. Ezzati M., Lopez A.D., 2004. Regional, disease specific patterns of smoking-attributable mortality in 2000. Tob Control 13:388–395.CrossRefGoogle Scholar
  47. Fisher B., Costantino J.P., Wickerham D.L., et al., 1998. Tamoxifen for prevention of breast cancer: Report of the National Surgical adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388.CrossRefGoogle Scholar
  48. Fleischauer A.T. et al., 2000. Garlic consumption and cancer prevention: meta-analyses of colorectal and stomach cancers. Am J Clin Nutr 72(4):1047–1052.Google Scholar
  49. Foster R.S., 2003. The Financial Outlook for Medicare. Testimony before the House Committee on Energy and Commerce Subcommittee on Health.Google Scholar
  50. Fowke J.H. et al., 2003. Urinary isothiocyanate levels, brassica and human breast cancer. Cancer Res 63(14):3980–3986.Google Scholar
  51. Garland C.F., Garland F.C., Gorham E.D., 1993. Rising trends in melanoma: an hypothesis concerning sunscreen effectiveness. Ann Epidemiol 3:103–110.CrossRefGoogle Scholar
  52. Giardiell F.M., Yang V.W., Hylind L.M. et al., 2002. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 346:1054–1109.CrossRefGoogle Scholar
  53. Goldman D.P., Shekelle P.G., Bhattacharya J. et al., 2004. Health status and medical treatment of the future elderly. Final Report. TR-169-CMS. Rand Health.Google Scholar
  54. Greaves M.F., 1997. Etiology of acute leukemia. Lancet 349:344–349.MathSciNetCrossRefGoogle Scholar
  55. Greenwald P., 1995. Introduction: history of cancer prevention and control. In: Greenwald P., Kramer B.S., Weed D.L. (Eds): Cancer Prevention and Control. New-York: Marcel Dekker, Inc.Google Scholar
  56. Greenwald, P., 2002. Cancer prevention clinical trials. J Clin Oncol 20:14S–22S.Google Scholar
  57. Greenwald P., Cullen J.W., 1985. The new emphasis in cancer control. J Natl Cancer Inst 74:543–551.Google Scholar
  58. Greenwald P. Cullen J.W., McKenna J.W., 1987. Cancer prevention and control: from research through applications. J Natl Cancer Inst 79:389–400.Google Scholar
  59. Habel L.A., Friedman G.D., 2006. Pharmaceticals other than hormons. In: Schottenfeld D., Fraumeni J.F. Jr. (Eds). Cancer Epidemiology and Prevention. 3rd edition. Oxford: Oxford University Press. pp. 489–506.Google Scholar
  60. Halfon N., Hochstein M., 2002. Life course health development: an integrated framework for developing health, policy, and research. Milbank Q 80:433–479.CrossRefGoogle Scholar
  61. Henningfield J.E., 1985. Nicotine: An Old-Fashioned Addiction. New York, NY: Chelsea House Publishers, pp. 96–98.Google Scholar
  62. Herlyn D., Birebent B., 1999. Advances in cancer vaccine development. Annals of Medicine 31(1):66–78.CrossRefGoogle Scholar
  63. Hiatt R.A., Rimer B.K., 1999. A new strategy for cancer control research. Cancer Epidemiol Biomarkers Prev 8:957–964.Google Scholar
  64. Hiatt R.A., Rimer B.K., 2006. Principles and applications of cancer prevention and control interventions. In: Schottenfeld D., Fraumeni J.F. Jr. (Eds). Cancer Epidemiology and Prevention. 3rd edition. Oxford: Oxford University Press. pp. 1283–1291.Google Scholar
  65. Hochreiter A.E., Xiao H., Goldblatt E.M. et al., 2006. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 12(10):3184–3192.CrossRefGoogle Scholar
  66. Holmes M.D., Chen W.J., Feskanich D. et al., 2005. Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486.CrossRefGoogle Scholar
  67. Hong W.K., Endicott J., Itri L.M. et al., 1986. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 315:1501–1505.CrossRefGoogle Scholar
  68. Hong W.K., Lippman S.M., Itri L.M. et al., 1990. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795–801.CrossRefGoogle Scholar
  69. Hwang L.C., Fein S., Levitsky H., Nelson W.G., 1999. Prostate cancer vaccines: current status. Seminars in Oncology 26(2):192–201.Google Scholar
  70. IARC Working Group, 2002. IARC Handbooks of Cancer Prevention, Vol. 6. Weight control and physical activity. Lyon, France: IARC Press, pp. 1–315.Google Scholar
  71. IARC, 2002. Weight, Control and Physical Activity. Lyon: IARC.Google Scholar
  72. IARC, 2004. Tobacco Smoke and Involuntary Smoking. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Vol. 83. Lyon: IARC.Google Scholar
  73. James S.J., Progribna M., Progribny I.I. et al., 1999. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr 70:495–501.Google Scholar
  74. Janne P.A., Mayer R.J., 2000. Chemoprevention of colorectal cancer. N Engl J MedNEJM 342:1960–1968.CrossRefGoogle Scholar
  75. Jemal A., Thomas A., Murray T et al., 2002. Cancer statistics. CA Cancer J Clin 52:23–47.CrossRefGoogle Scholar
  76. Jha P., Chaloupka F.J., Corrao M. et al., 2006. Reducing the burden of smoking world-wide: effectiveness of interventions and their coverage. Drug Alcohol Rev 25(6):597–609.CrossRefGoogle Scholar
  77. Johnston L., 2001. Changing Demographic Patterns of Adolescent Smoking over the Past 23 years: National Trends from the Monitoring the Future Study. Changing Adolescent Smoking Prevalence. Smoking and Tobacco Control Monograph No. 14. NIH Publ. No. 02-5086. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, pp. 9–34.Google Scholar
  78. Kaaks R., Van Noord P.A.H., Den Tonkelaar I., et al., 1998. Breast cancer incidence in relation to height, weight and body-fat distribution in the Dutch “DOM” cohort. Int J Cancer 76(5):647–651.CrossRefGoogle Scholar
  79. Keloff G.J., Boone C.W., Crowell J.A. et al., 1994. Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 3:85–98.Google Scholar
  80. Khuder S.A., Mutgi A.B., 2001. Breast cancer and NSAID use: a meta-analyses. Br J Cancer 84(9):1188–1192.CrossRefGoogle Scholar
  81. Kim Y.S., Milner J.A., 2005. Targets for indole-3-carbinol in cancer prevention. J Nutr Biochem 16(2):65–73.MATHCrossRefGoogle Scholar
  82. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., Nathan D.M., 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393–403.CrossRefGoogle Scholar
  83. Kopstein A., 2001. Trends in adolescent smoking in the United States: data from the national household survey on drug abuse 1994 through 1998. Changing Adolescent Smoking Prevalence. Smoking and Tobacco Control Monograph No. 14. NIH Publ. No. 02-5086. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, pp. 51–68.Google Scholar
  84. Koutsky L.A., Ault K.A., Wheeler C.M. et al., 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645–1651.CrossRefGoogle Scholar
  85. Koushik A., Hunter D.J., Spiegelman D. et al., 2007. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 99(19):1471–1483.CrossRefGoogle Scholar
  86. Kravchenko J., Goldschmidt-Clermont P.J., Powell T., Stallard E., Akushevich I., Cuffe M.S., Manton K.G., 2005. Endothelial progenitor cell therapy for atherosclerosis: the philosopher’s stone for an aging population? Sci Aging Knowledge Environ Jun 22; 2005 (25):18.Google Scholar
  87. Krebs-Smith S.M., Cook A., Subar A.F. et al., 1995. U.S adults’ fruit and vegetable intakes, 1989 to 1991: a revised baseline for the Health People2000 objective. Am J Public Health 85:1623–1629.CrossRefGoogle Scholar
  88. Krebs-Smith S.M., Cook A., Subar A.F. et al., 1996. Fruit and vegetable intakes in children and adolescents in the United States. Arch. Pediatr Adolesc Med 150:81–86.Google Scholar
  89. Kricker A., Armstrong B.K., Hughes A.M. et al., 2007. Personal sun exposure and risk of non-Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer 122(1):144–154.CrossRefGoogle Scholar
  90. Kulasingam S.I., Myers E.R., 2003. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290(6):781–789.CrossRefGoogle Scholar
  91. Kurie J.M., Lee J.S., Khuri F.R. et al., 2000. N(4-hydroxphenyl) retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 6:2973–2979.Google Scholar
  92. Kurie J.M., Lotan R., Lee J.J. et al., 2003. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 95:206–214.CrossRefGoogle Scholar
  93. Kutz G. (2006). Nutrigenic testing: test purchased from four web sites misled consumers. At:
  94. Labayle D., Fischer D., Vielh P. et al., 1991. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101:635–639.Google Scholar
  95. Lam S., MacAulay C., Le Riche J.C. et al., 2002. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 94:1001–1009.Google Scholar
  96. Lee R., Tuljapurkar S., 1998. Population Forecasting for Fiscal Planning: Issues and Innovations. Burch Working Paper No. B98-05, University of California, Berkeley, December.Google Scholar
  97. Lee R., Miller T., 2002. An approach to forecasting health expenditures, with application to the U.S. Medicare System. Health Serv Res, 37(5), October 2002, pp. 1365–1386CrossRefGoogle Scholar
  98. Lee I-M., Oguma Y., 2006. Physical activity. In: Cancer Epidemiology and Prevention. Schottenfeld D., Fraumeni J.F .Jr. (Eds). 3rd edition. Oxford: Oxford University PressGoogle Scholar
  99. Lee J.S., Lippman S.M., Benner S.E. et al., 1994. Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. J Clin Oncol 12:937–945.Google Scholar
  100. Lee J.M., Kopans D.B., McMahon P.M. et al., 2008. Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging – Markov Monte Carlo decision analysis. Radiology Mar; 246(3):763–771CrossRefGoogle Scholar
  101. Linos E., Raine T., Alonso A. et al., 2007. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst 99(20):1544–1550.CrossRefGoogle Scholar
  102. Lippman S.M., Hong W.K., 2002. Cancer prevention science and practice. Cancer Res 62:5119–5125.Google Scholar
  103. Lippman S.M., Batsakis J.G., Toth B.B. et al., 1993. Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 328:15–20.CrossRefGoogle Scholar
  104. Lippman S.M., Lee J.J., Karp D.D. et al., 2001. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93:605–618.CrossRefGoogle Scholar
  105. Liu R.H., 2004. Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134:3479S–3485S.Google Scholar
  106. Lock S., Reynolds L.A., Tansey E.M. (Eds), 1998. Ashes to Ashes: The History of Smoking and Health. 2nd edition, Amsterdam: Rodopi. 256 pages.Google Scholar
  107. London S.J. et al., 2000. Isothiocyanates, glutathione-S-transferase M1 and T1 polymorphisms, and lung cancer risk: a prospective study of men in Shanghai, China. Lancet 356(9231):724–729.CrossRefGoogle Scholar
  108. Long L., Glover R.T., Kaufman H.L., 1999. The next generation of vaccines for the treatment of cancer. Curr Opin Mol Ther 1:57–63.Google Scholar
  109. Lopez A.D., Shibuya K., Rao C. et al., 2006. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 27:397–412.CrossRefGoogle Scholar
  110. Lundholm K., Gelin J., Hyltander A. et al., 1994. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 54:5602–5606.Google Scholar
  111. Mandel J., Bond J., Church T. et al., 1993. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328:1365–1371.CrossRefGoogle Scholar
  112. Manton K.G., Stallard E., 1988. Chronic Disease Risk Modeling: Measurement and Evaluation of the Risks of Chronic Disease Processes.//In the Griffin Series of the Biomathematics of Diseases. London, England: Charles Griffin Limited.Google Scholar
  113. Manton K.G., Stallard E., Vaupel J.W., 1986. Alternative models for the heterogeneity of mortality risks among the Aged. J Am Stat Assoc 81(395):635–644CrossRefGoogle Scholar
  114. Manton K.G., Gu X., Lamb V.L., 2006. Change in chronic disability from 1982 to 2004/2005 as measured by long-term changes in function and health in the U.S. elderly population. Proc Natl Acad Sci U S A. 103(48):18374–18379.CrossRefGoogle Scholar
  115. Manton K.G., Akushevich I., Kulminski A., 2008. Human mortality at extreme ages: data from the national long term care survey and linked Medicare records, Math Popul Stud 15:137–159.Google Scholar
  116. Manton K.G., Lowrimore G.R., Ullian A.D., Gu X., Tolley H.D., 2007b. Labor force participation and human capital increases in an aging population and implications for U.S. research investment. Proc Natl Acad Sci U S A. 104(26):10802–10807.Google Scholar
  117. Marshall J.R., Freudenheim J.O., 2006. Alcohol. In: Cancer Epidemiology and Prevention. Schottenfeld D., Fraumeni J.F. Jr. (Eds). 3rd edition. Oxford: Oxford University.Google Scholar
  118. Martin K.R., 2006. Targeting apoptosis with dietary bioactive agents. Exp Biol Med 231(2):117–129.Google Scholar
  119. Mathers C.D., Loncar D., 2006. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3(11):e442.CrossRefGoogle Scholar
  120. Mayr C.A., Woodall A.A., Ames B.N., 1999. In Preventive Nutrition: The Comprehensive Guide for Health Professionals. Eds Bendich A., Deckelbaum R.J. Totowa, NJ: Humana.Google Scholar
  121. McMahon P.M., Kong C.Y., Johnson B.E. et al., 2008. Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology 248:278–287.Google Scholar
  122. McTiernan A., Kooperberg C., White E. et al., 2003. Recreational physical activity and the risk of breast cancer in postmenopausal women: The Women’s Health Initiative Cohort Study. JAMA 290(10):1331–1336.CrossRefGoogle Scholar
  123. Meyskens, F.L. (2004). Cancer prevention, screening, and early detection. In: Abeloff, M.D., Armitage, J.O., Niederhuber, J.E., Kastan, M.B., McKenna, W.G. (eds.) Clin Oncol. 3rd edition, pp. 425–472. Amsterdam: Elsevier.Google Scholar
  124. Michalowski J., 2002. COX-2 inhibitors: cancer trials test new uses for pain drug. J Natl Cancer Inst 94(4):248–249.Google Scholar
  125. Miller T., 2001. Increasing longevity and Medicare expenditures. Demography, 38(2), May 2001, pp. 215–226CrossRefGoogle Scholar
  126. Minev B.R., Chavex F.L., Mitchell M.S., 1999. Cancer vaccines: novel approaches and new promise. Pharmacol Ther 81(2):121–139.CrossRefGoogle Scholar
  127. MMWR, 2004. Trends in intake of energy and macronutrients – United States, 1971–2000. Mor Mortal Wkly Rep 53:80–82.Google Scholar
  128. Moon, T.E., Levine, N., Cartmel, B. et al, 1997. Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epi Biom Prev 6:949–956.Google Scholar
  129. Muller A.D., Sonnenberg A., 1995. Protection by endoscopy against death from colorectal cancer. A case–control study among veterans. Arch Intern Med 155:1741–1748.CrossRefGoogle Scholar
  130. Murphy K.M., Topel R.H. (2006) The value of health and longevity. J Political Econ 114:871–904.CrossRefGoogle Scholar
  131. Myers E.R., McCrory D.C., Nanda K. et al., 2000. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151(12):1158–1171.Google Scholar
  132. National Cancer Institute, Acrylamide in Foods. Fact Sheet.
  133. National Cancer Institute, Artificial Sweeteners and Cancer. Questions and Answers.
  134. National Cancer Institute, Heterocyclic Amines in Cooked Meats
  135. Nieburgs H.E., Vali V.E., 2007. Oncogenic cofactors that may act in synergistic, interactive or sequential manner on various target sites. Cancer Detection and Prevention 31(6): back cover.Google Scholar
  136. New York City Cancer Committee, 1994. New York City Cancer Committee: History of the America society for the control of cancer, 1913–1943. New York: New York City Cancer Committee.Google Scholar
  137. Nutrition and Physical Activity Guidelines 2006. American Cancer Society. At:
  138. Obesity and Cancer: questions and answers. National Cancer Institute. At:
  139. Parker E.D., Folsom A.R., 2003. Intentional weight loss and incidence of obesity-related cancers. The Iowa Women’s Health Study. Int J Obes Relat Metab Disord 27(12):1447–1452.CrossRefGoogle Scholar
  140. Parkhurst M.R., Riley J.P., Igarashi T. et al., 2004. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lumphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 10:4688–4698.CrossRefGoogle Scholar
  141. Peto R., Darby S., Deo H. et al., 2000. Smoking, smoking cessation and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ 321:323–329.CrossRefGoogle Scholar
  142. Phatak P., Burger A.M., 2007. Telomerase and its potential for therapeutic intervention. Br J Pharmacol 152:1003–1011.CrossRefGoogle Scholar
  143. Plummer M., Vivas J., Lopez G. et al., 2007. Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst 99(2):137–146.CrossRefGoogle Scholar
  144. Proctor R.N., 2001a. Commentary: Schairer and Schoninger’s forgotten tobacco epidemiology and the Nazi quest for racial purity. Int J Epidemiol 30:31–34.Google Scholar
  145. Proctor R.N., 2001b. Commentary: pioneering research into smoking and health in Nazi Germanu – the “Wissenschaftliches Institute zur Erforschung der Tabakgefahren” in Jena. Int J Epidemiol 30:35–37.Google Scholar
  146. Rao C., Hart J., Chow A. et al., 2008. Does preservation of the sub-valvular apparatus during mitral valve replacement affect long-term survival and quality of life? A Microsimulation Study. J Cardiothorac Surg 3(1):17.CrossRefGoogle Scholar
  147. Review of Assumptions and Methods of the Medicare Trustees’ Financial Projections. December 2000.Google Scholar
  148. Rogers E., 1993. Diffusion of Innovation. London: The Free Press.Google Scholar
  149. Rokkas T., Pistolas D., Sechopoulos P. et al., 2007. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 5(12):1413–1417.CrossRefGoogle Scholar
  150. Ross J.A., 2000. Dietary flavonoids and the MLL gene: a pathway to infant leukemia? PNAS 97(9):4411–4413.CrossRefGoogle Scholar
  151. Ross J.A., Potter J.D., Reaman G.H., Pendergrass T., Robinson L.L., 1996. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes Control 7:581–590.Google Scholar
  152. Samad A.K., Taylor R.S., Marshall T., Chapman M.A., 2005. A meta-analysis of the association of physical activity with reduced risk of colorectal cancer. Coloraectal Dis 7(3):204–213.CrossRefGoogle Scholar
  153. Sandler R.S., Halabi S., Baron J.A. et al., 2003. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890.Google Scholar
  154. Schatzkin A., Lanza E., Corle D., et al. (2000). Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 342:1149–1155.CrossRefGoogle Scholar
  155. Scholm J., Tsang K.Y., Kantor J.A., Abrams S.I., 1998. Cancer vaccine development. Expert Opin Investig Drugs 7(9):1439–1452.CrossRefGoogle Scholar
  156. Spector L.G.. Xie Y., Robinson L.L. et al., 2005. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the Children’s Oncology Group. Cancer Epidemiol Biomarkers Prev 14(3):651–655.Google Scholar
  157. Sporn M.B., Dunlop N.M., Newton D.L. et al., 1976. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338.Google Scholar
  158. Steinbach G., Lynch P.M., Phillips R.K. et al., 2000. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl K Med 342:1946–1952.CrossRefGoogle Scholar
  159. Stewart G.G., 1967. A history of the medicinal use of tobacco, 1492–1860. Med Hist 11(3):228–268.Google Scholar
  160. Strachan T., Read A.P., 1999. Human Molecular Genetics 2. 2nd edition. New York, NY: John Willey & Son, Publishers. BIOS Scientific Publishers, LTD. 576 pages.Google Scholar
  161. Surveillance, Epidemiology and End Results (SEER) Program, 2003. SEER Stat Database: Mortality – All COD, Public Use with State, Total U.S. (1969–2000). Underlying mortality data provided by NCHS (, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
  162. Swan J., Breen N., Coates R.J. et al., 2003. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 97:1528–1540.CrossRefGoogle Scholar
  163. Taningher M., Malacarne D., Izzotti A. et al, 1999. Drug metabolism polymorphisms as modulator of cancer susceptibility. Mutat Res 436:227–261.CrossRefGoogle Scholar
  164. Thompson I.M., Kouril M., Klein E.A. et al., 2001. The Prostate Cancer Prevention Trial: current status and lessons learned. Urology 57(Suppl. 1):230–234.CrossRefGoogle Scholar
  165. Thompson I.M., Goodman P.J., Tangen C.M. et al., 2003. The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224.CrossRefGoogle Scholar
  166. Thune I., Furberg A.S., 2001. Physical activity and cancer risk: dose-response and cancer, all sites and site-specific. Med. Sci. Sports Exerc. 33(6), Suppl., pp. S530–S550.Google Scholar
  167. Thun M.J., Henley S.J., 2006. Tobacco. In: Schottenfeld D., Fraumeni J.F. Jr. (eds.). Cancer Epidemiology and Prevention. 3rd edition. Oxford: Oxford University Press, pp. 217–242.Google Scholar
  168. Thun M.J., Henley S.J., Patrono C., 2002. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94(4):252–266.Google Scholar
  169. Trentham-Dietz A., Newcomb P.A., Egan K.M. et al., 2000. Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control 11(6):533–542.CrossRefGoogle Scholar
  170. Turkkan J.S., Kaufman N.J., Rimer B.K., 2000. Transdisciplinary tobacco use research centers: a model collaboration between public and private sectors. Nicotine Tob Res 2:9-13.U.S. Department of Health and Human Services, 1990. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. Rockville, MD. U.S. Department of Health and Human Services, Public Health Service, centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.Google Scholar
  171. US DHHS, 1990. The Health Benefits of Smoking Cessation. A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.Google Scholar
  172. U.S. Department of Health and Human Services, 2000. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.Google Scholar
  173. U.S. Preventive Services Task Force, 2002. Guide to Clinical Preventive Services. 3rd edition. Recommendations. Washington, D.C.: Office of Disease Prevention and Health Promotion.Google Scholar
  174. US Census Bureau, 2006. World Information. Washington, D.C., USA: US Census Bureau.
  175. Vainio H., Bianchini F., 2002. IARC Handbooks of Cancer Prevention. Volume 6: Weight Control and Physical Activity. Lyon, France: IARC Press.Google Scholar
  176. Vainio H., Kaaks R., Bianchini F, 2002. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev 11(Suppl2):S94–S100.Google Scholar
  177. Vaupel J.W., Manton K.G., Stallard E., 1979. The impact of heterogeneity in individual frailty on the dynamics of mortality. Demography 9:439–454CrossRefGoogle Scholar
  178. Veronesi U., De Palo G., Marubini E. et al., 1999. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 91:1847–1856.CrossRefGoogle Scholar
  179. Viner J.L., Hawk E., Lippman S.M., 2006. Cancer chemoprevention. In: Schottenfeld D., Fraumeni J.F. Jr. (Eds.). Cancer Epidemiology and Prevention. 3rd edition. Oxford: Oxford University Press. pp. 1318–1340.Google Scholar
  180. Vonderheide R.H., Domchek S.M., Schultze J.L. et al., 2004. Vaccination of cancer patients against telomerase induces functional antitumor CD8 T lymphocytes. Clin Cancer Res 10:828–839.CrossRefGoogle Scholar
  181. Wattenberg L.W., 1996. Chemoprevention of cancer. Prev Med 25:4445.CrossRefGoogle Scholar
  182. White L.K., Wright W.E., Shay J.W., 2001. Telomerase inhibitors. Trends Biotechnol 19(3):114–120.CrossRefGoogle Scholar
  183. Willet W.C., Colditz G.A., Mueller N.E., 1996. Strategies for minimizing cancer risk. Sci Am 275(3):88–91, 94–95.CrossRefGoogle Scholar
  184. Wilson J.W., Enns C.W., Goldman J.D. et al, 1997. Data tables: combined results from USDA’s 1994 and 1995 Continuing Survey of Food Intakes by Individuals and 1994 and 1995 Diet and Health Knowledge Survey. Beltsville Human Nutrition Research Center, Riverdale, MD.Google Scholar
  185. Wilson S., Jones L., Coussens C., Hanna K. (Eds), 2002. Cancer and the Environment. Gene-environment Interaction. Washington, D.C.: Institute of Medicine. National Academy Press.Google Scholar
  186. Wingo P.A., Ries L.A.G., Giovino G.A. et al., 1999. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 91:675–690.Google Scholar
  187. World Cancer Research Fund, American Institute for Cancer Research. Food, Nutrition and the Prevention of Cancer: A Global Perspective. Washington D.C.: American Institute for Cancer Research, 1997. At:
  188. Wright W.E., Platyszek M.A., Rainey W.E. et al., 1996. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 18:173–179.CrossRefGoogle Scholar
  189. Yashin A.I., Manton K.G., 1997. Effects of unobserved and partially observed covariate processes on system failure: a review of models and estimation strategies. Stat Sci 12(1):20–34.MATHMathSciNetCrossRefGoogle Scholar
  190. Yashin A.I., Iachine I.A., Begun A.Z., 2000. Mortality modeling: a review. Math Popul Stud 8(4):305–332MATHMathSciNetCrossRefGoogle Scholar
  191. Young R.C., Wilson C.M., 2002. Cancer prevention: past, present and future. Clin Can Res 8:11–16.Google Scholar
  192. Zhou J.R., Yu L., Zhong Y. et al., 2003. Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr 133:516–521.Google Scholar
  193. Zhou J.R., Yu L., Mai Z. et al., 2004. Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int J Cancer 108:8–14.CrossRefGoogle Scholar
  194. Ziegler R.G., Hoover R.N., Nomura A.M. et al., 1996. Relative weight, weight change, height, and breast cancer risk in Asian American women. J Natl Cancer Inst 88(10):650–660.CrossRefGoogle Scholar
  195. Zu K., Ip C., 2003. Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. Cancer Res 63:6988–6995.Google Scholar
  196. α-Tocoferol, β-Carotene Cancer Prevention Study Group, 1994. The effect of vitamin E and β-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029–1035.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • K.G. Manton
    • 1
  • Igor Akushevich
    • 1
  • Julia Kravchenko
    • 1
  1. 1.Duke UniversityDurhamUSA

Personalised recommendations